Do Genetic Polymorphisms Modulate Response Rate and Toxicity of Cisplatin Associated With Radiotherapy in Laryngeal Squamous Cell Carcinoma? A Case Report

Autor(es)

Lopes-Aguiar, Leisa ^[1] ; Visacri, Marilia Berlofa ^[2] ; Lopes Nourani, Carolina Marques ^[1] ; Dias Costa, Ericka Francislaine ^[1] ; Silva Nogueira, Guilherme Augusto ^[1] ; Penna Lima, Tathiane Regine ^[1] ; Pincinato, Eder Carvalho ^[1] ; Moriel, Patricia ^[2] ; Carrasco Altemani, Joao Mauricio ^[3] ; Passos Lima, Carmen Silvia ^[1]

Afiliação do(s) autor(es)

^[1] Univ Estadual Campinas, Fac Med Sci, Dept Internal Med, BR-13083970 Campinas, SP - Brazil

^[2] Univ Estadual Campinas, Fac Med Sci, Dept Clin Pathol Brazil, BR-13083970 Campinas, SP - Brazil

^[3] Univ Estadual Campinas, Fac Med Sci, Dept Radiol, BR-13083970 Campinas, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: MEDICINE; v. 94, n. 16 APR 2015.
• Citações Web of Science: 5

Resumo

Cisplatin (CDDP) plus radiotherapy (RT) has been used to treat advanced laryngeal squamous cell carcinoma (LSCC) patients. Single nucleotide polymorphisms (SNPs) may be responsible for differences in chemo/radiosensitivity and side effects in those patients. We reported an advanced LSCC patient, who obtained durable complete response and unexpected pronounced toxicity during CDDP and RT, possibly due to SNPs in genes that modulate the effects of this therapeutic modality. Case presentation: A 30-year-old man with advanced LSCC obtained durable complete response and severe alopecia and pancytopenia after standard and reduced doses of CDDP and RT. Analyses of SNPs revealed that the patient presented GSTT1 deletion, variant MSH3 1045ThrThr, wild GSTP1 105IleIle, and wild BAX -248GG genotypes, which were previously described in association with abnormal detoxification, DNA repair, and damaged cell apoptosis, respectively. Seven other advanced LSCC patients with GSTT1 gene, MSH3 AlaAla or AlaThr, GSTP1 IleVal or ValVal, and BAX GA or AA genotypes served as controls of the study. Only 1 control presented complete response; the other 6 controls obtained partial response of short duration. Four and 3 controls presented grade 1 or 2 and grade 3 anemia or leukopenia during treatment, respectively. The CDDP level in urine collected after CDDP infusion in the reported patient was lower than the median value obtained in controls, suggesting a higher amount of intracellular CDDP in the reported case. The data suggest, for the first time, that inherited abnormalities in intracellular detoxification of CDDP, DNA repair of lesions induced by CDDP and RT, and damaged cell apoptosis may alter treatment response and toxicity in LSCC, but should be confirmed by large pharmacogenomic studies. (AU)

• Processo FAPESP: 12/01807-2 - Farmacogenética da cisplatina em portadores de carcinoma de células escamosas de cabeça e pescoço
• Beneficiário: Carmen Silvia Passos Lima
• Modalidade de apoio: Auxílio à Pesquisa - Regular